IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#566
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$3.1B
Chintu Patel
Amneal Pharmaceuticals, Inc. develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products. The company operates through three segments: Generics, Specialty, and AvKARE. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies.
Headcount
7.6K
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
X-AXIS: EV/EBITDA (LOWER = CHEAPER) | Y-AXIS: ROE (HIGHER = ELITE) | RED CIRCLE = AMRX ANALYSIS TARGET
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 32.9% | 20.5% | 48.8% | 30.6% | 24.4% | 7.7% | 0.9% | 32.0x | $148.6B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.4% | 7.5% | 68.3% | 19.5% | 18.2% | 29.0% | 0.0% | 0.0x | $84M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | - | - | - | - | - | - | - | - | $0 | VS | |
$AMRX Amneal Pharmaceuticals, Inc. | 61 | 48 | 73 | 76 | 50.6x | 19.2x | -403.7% | 2.5% | 37.4% | 12.9% | 3.1% | 11.8% | 0.0% | - | $3.1B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -1.9% | 0.9% | 44.1% | 2.5% | 1.0% | 6.7% | 0.0% | 0.2x | - | REF |
Amneal Pharmaceuticals, Inc. (AMRX) receives a "Hold" rating with a composite score of 61.4/100. It ranks #566 out of 7,333 stocks in our coverage universe and carries a 3-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
HQ Base
Pending Verification
Outperforming peers — winners tend to keep winning over 3-12 months
Trading at a discount to fundamentals — favorable entry valuation
Average quality profile
Low volatility — smoother ride and historically better risk-adjusted returns
Moderate investment profile
Mid-range overall rating
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
Projection based on user-defined inputs. Re-calculated daily against current market data.
Reverse DCF Framework — Mauboussin Methodology
Institutional-grade Reverse DCF analysis. This model identifies the growth hurdles embedded in current market prices. When implied growth is significantly lower than historical or projected rates, a margin of safety may exist. Re-audited daily.
No analyst ratings for AMRX.
View All Ratings| Factor | Global | Sector | Tilt |
|---|---|---|---|
| PROFITABILITY | 48 | 39 | +9ALPHA |
| MOMENTUM | 76 | 81 | -5NEUTRAL |
| VALUATION | 73 | 74 | -1NEUTRAL |
| INVESTMENT | 45 | 84 | -39DRAG |
| STABILITY | 85 | 90 | -5NEUTRAL |
| SHORT INT | 41 | 37 | +4NEUTRAL |
Global = full universe. Sector = relative to industry peers. Positive tilt indicates idiosyncratic strength.
ROIC 3.0% vs WACC 6.2% (spread -3.2%)
GM 37% vs sector 44%, OM 13% vs sector 3%
Capital turnover 0.33x, R&D intensity 6.9%
Rev growth 12%, 8yr history
Interest coverage 2.2x, Net debt/EBITDA 33.7x
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
We rate Amneal Pharmaceuticals, Inc. (AMRX) as a Hold with a composite score of 61.4/100 at a current price of $14.70. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling.
Amneal Pharmaceuticals, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 61.4/100 places it at rank #566 in our full universe.
The near-term outlook is constructive, with revenue growing at 12% and momentum in the 76th percentile confirming positive market sentiment. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy.
No Moat
Low
Poor
Undervalued
Value factor score of 73 suggests attractive pricing.
Positive momentum indicates institutional accumulation.
Stable competitive position in a defensive sector.
Elevated P/E ratio of 50.6x leaves little room for execution misses.
Vulnerability to macroeconomic shocks and interest rate volatility.
Amneal Pharmaceuticals, Inc. represents a hold based on multi-factor quantitative performance.
Our model assigns Amneal Pharmaceuticals, Inc. a Hold rating, with a composite score of 61.4/100 and 3 out of 5 stars. Ranked #566 of 7,333 stocks, AMRX presents a mixed quantitative picture — neither compelling enough to initiate new positions nor weak enough to warrant selling. Investors already holding may consider maintaining their position while monitoring for changes in the factor profile.
With a quality score of 48/100, AMRX shows adequate but unremarkable business quality. The company reports a return on equity of -403.7% (sector avg: -1.9%), gross margins of 37.4% (sector avg: 44.1%), net margins of 3.1% (sector avg: 1.0%). This suggests the company generates acceptable returns but may lack the competitive positioning or operational efficiency to stand out from peers.
AMRX carries a solid value score of 73/100, pointing to an attractively priced stock relative to peers. Key valuation metrics include a P/E ratio of 50.58x, an EV/EBITDA of 19.23x. This score suggests reasonable compensation for the risks involved, with potential upside if the market recognizes the stock's underlying worth.
With an investment score of 45/100, AMRX exhibits moderate growth-oriented spending. Key growth metrics include revenue growth of 11.8% vs. a sector average of 6.7% and a return on assets of 2.5% (sector: 0.9%). The company appears to be balancing growth investments with capital returns, though the pace of investment may not be enough to accelerate top-line growth meaningfully.
AMRX shows strong momentum characteristics with a score of 76/100. The stock has been trending above key moving averages, indicating solid demand from institutional buyers. Revenue growth stands at 11.8% year-over-year, while a beta of 0.87 reflects its sensitivity to broader market moves. This level of momentum typically signals sustained investor confidence and favorable near-term price action.
Amneal Pharmaceuticals, Inc. earns an excellent stability score of 85/100, reflecting low price volatility and a conservatively managed balance sheet. Key stability metrics include a beta of 0.87. Stocks with this level of stability tend to act as portfolio anchors, providing downside protection during market corrections while still participating in broad market advances.
The short interest score of 41/100 for AMRX suggests somewhat elevated bearish positioning by institutional traders. With a $3.1B market cap (mid-cap), Amneal Pharmaceuticals, Inc. may experience above-average volatility. Investors should consider whether the short thesis has merit or if it creates a potential short-squeeze opportunity.
Amneal Pharmaceuticals, Inc. is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #566 of 7,333 overall (92nd percentile). Key comparisons include ROE of -403.7% trailing the -1.9% sector median and operating margins of 12.9% above the 2.5% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While AMRX currently exhibits a HOLD profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Key factor gap
Stability (85) vs Short Int. (41) — closing this gap could shift the rating.
EV/EBITDA 68% ABOVE SECTOR MEDIAN
ROE 21146% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 15% BELOW SECTOR MEDIAN
Above 50MA
37.18%
Net New Highs
+51081
Amneal Pharmaceuticals, Inc. announced that it has been added to the S&P SmallCap 600 Index and, in a separate move, entered into a research collaboration and option agreement with KeifeRx to develop KFRX06, a preclinical candidate targeting the LRRK2 gene linked to Parkinson's disease. These developments could broaden Amneal’s investor base through index inclusion while expanding its neuroscience pipeline via early-stage Parkinson’s research. Next, we’ll explore how joining the S&P SmallCap...
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is among the 7 Cheap Pharmaceutical Stocks to Buy According to Hedge Funds. The next stock on our list is Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX). TheFly reported on Feb 11 that JP Morgan raised AMRX price target by $4 and maintained a Buy rating. Separately, on January 29, Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) […]
As February begins, U.S. stock indexes have surged, with the Dow Jones Industrial Average gaining 515 points and the S&P 500 nearing a record high. In this buoyant market environment, investors often look towards growth companies with strong insider ownership as these firms can offer potential stability and alignment of interests between management and shareholders.
The global health and wellness sector is projected to reach $6 trillion in annual consumer spending in 2026, driven by demand for functional products and stricter clean-label regulations. Five companies are capitalizing on this trend: Doseology Sciences launched caffeine-based energy pouches; Amneal Pharmaceuticals introduced a new brand identity and plans an Accessibility Index; Prestige Consumer Healthcare expanded its dry eye care portfolio; Viking Therapeutics advanced its obesity drug portfolio with Phase 3 trials; and Insulet expanded its automated insulin delivery system to the Middle East.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.